Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
Veeva Systems (NYSE:VEEV) reported fiscal 2027 second-quarter revenue of $928 million and non-GAAP operating income of $416 million, with Chief Executive Officer Peter Gassner saying results exceeded the company’s guidance. Management highlighted record CRM performance, broad commercial-cloud moment
August 26, 2026 — Drug discovery can begin with 5,000 to 10,000 compounds, narrow to approximately 250 entering preclinical development , around five reaching clinical trials and ultimately produce just one approved medicine —highlighting why identifying weak drug candidates earlier can be critical to pharmaceutical R&D.
August 26, 2026 — Investor attention is building around several lower-priced small-cap stocks trading near the $0.30 range, including VivoSim Labs, Inc. (NASDAQ: VIVS), IGC Pharma, Inc. (NYSE: IGC), Algorhythm Holdings, Inc. (NASDAQ: RIME) and Xiao-I Corporation (NASDAQ: AIXI), as company-specific catalysts across AI, biotechnology, drug development and logistics technology drive trading interest.VivoSim Labs (NASDAQ: VIVS) — AI Drug Toxicity and FDA NAM Momentum
Eli Lilly looks like a strong long-term investment thanks to its booming obesity drugs and Alzheimer's treatment, and to Billionaire Ken Griffin's investment.
VanEck's concentrated 26-stock portfolio has outpaced Fidelity's broader 334-holding fund over five years, but at a steeper cost and higher volatility.
VHT charges low fees and holds more than 400 stocks for broader diversification. IXJ's portfolio of 110 holdings includes international exposure -- but comes at a higher cost.
August 25, 2026 — VivoSim Labs, Inc. (NASDAQ: VIVS) is drawing investor attention following an initiation-of-coverage research report highlighting the company's NAMkind™ 3D human tissue models, AI-powered toxicology analytics, early commercial traction and potential opportunity from accelerating adoption of New Approach Methodologies (NAMs).
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...
Moderna's mRNA cancer vaccine breakthrough with Merck fueled a biotech rally, with the IBB near highs. Eli Lilly and Natera both show strong uptrends and possible breakouts.
IHE delivered 53.2% returns over one year with lower volatility and a 0.37% expense ratio, while PBE's quantitative biotech strategy carries higher risk.
Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 25.41% on an annualized basis producing an average annual return of 36.72%. Currently, Eli Lilly has a market capitalization of $1.12 trillion.
